EUROPEAN
COMMISSION

Brussels, 21.4.2021
C(2021) 2940 final

COMMISSION IMPLEMENTING DECISION

of 21.4.2021

withdrawing, at the holder's request, the marketing authorisation granted by Decision C(2000)1407 for "PegIntron - Peginterferon alfa-2b", a medicinal product for human use

(Text with EEA relevance)

(ONLY THE DUTCH TEXT IS AUTHENTIC)

COMMISSION IMPLEMENTING DECISION

of 21.4.2021

withdrawing, at the holder's request, the marketing authorisation granted by Decision C(2000)1407 for "PegIntron - Peginterferon alfa-2b", a medicinal product for human use

(Text with EEA relevance)

(ONLY THE DUTCH TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[1],

Having regard to the application submitted by Merck Sharp & Dohme B.V. on 23 March 2021 with a view to the withdrawal of the marketing authorisation for the medicinal product "PegIntron - Peginterferon alfa-2b",

Whereas:

(1) The placing on the market of the medicinal product "PegIntron - Peginterferon alfa-2b", which is entered in the Union Register of Medicinal Products under the number EU/1/00/131 was authorised by Commission Decision C(2000)1407 of 25 May 2000.

(2) Following the holder's request, that authorisation should be withdrawn,

HAS ADOPTED THIS DECISION:

Article 1

At the holder's request, the marketing authorisation granted by Decision C(2000)1407 of 25 May 2000 for the medicinal product "PegIntron - Peginterferon alfa-2b" is withdrawn.

[1] OJ L 136, 30.4.2004, p. 1.

Article 2

This Decision is addressed to Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Nederland.

Done at Brussels, 21.4.2021

For the Commission

Sandra GALLINA
Director-General